Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals’ Nutritional Products in China
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced a significant licensing agreement with Australia-based...
Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) unveiled longer-term results from the pivotal Phase III ASC4FIRST...
Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...
Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
US pharmaceutical giant Merck (NYSE: MRK) has revealed promising data from the Phase II waveLINE-007...
Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange
Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based...
AstraZeneca’s Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results
At the 66th American Society of Hematology (ASH) annual meeting, UK pharmaceutical major AstraZeneca (AZ,...
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...
Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study
Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I...
Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...
Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...
Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced
China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis...
Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer
Immunofoco, a biotechnology company specializing in immunotherapy, has announced that its self-developed autologous CAR-T product,...
Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial
Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...
AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics
US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...
Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials
China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...
NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...
Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...
Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...